Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 15/20 | 0.77 |
| ▸ | KDR | P35968 | 5/20 | 0.72 |
| ▸ | EPHB4 | P54760 | 4/20 | 0.72 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.72 |
| ▸ | FBP1 | P09467 | 2/20 | 0.72 |
| ▸ | AURKA | O14965 | 1/20 | 0.72 |
| ▸ | INSR | P06213 | 1/20 | 0.72 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.72 |
| ▸ | FLT4 | P35916 | 1/20 | 0.72 |
| ▸ | CLK1 | P49759 | 1/20 | 0.72 |
| ▸ | TEK | Q02763 | 1/20 | 0.72 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.72 |
| ▸ | EPHA2 | P29317 | 3/20 | 0.68 |
| ▸ | FLT1 | P17948 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL117984 | 1.00 | EGFR (0.77) | EGFRKDREPHB4ERBB2FBP1 | |
| SCHEMBL29623592 | 1.00 | EGFR (0.77) | EGFRKDREPHB4ERBB2FBP1 | |
| SCHEMBL208863 | 1.00 | EGFR (0.77) | EGFRKDREPHB4ERBB2FBP1 | |
| SCHEMBL1446383 | 0.90 | EGFR (0.70) | EGFRKDREPHB4ERBB2FBP1 | |
| SCHEMBL208516 | 0.90 | EGFR (0.70) | EGFRKDREPHB4ERBB2FBP1 | |
| SCHEMBL29623520 | 0.90 | EGFR (0.70) | EGFRKDREPHB4ERBB2FBP1 | |
| SCHEMBL14489893 | 0.90 | EGFR (0.70) | EGFRKDREPHB4ERBB2FBP1 | |
| SCHEMBL174651 | 0.90 | EGFR (0.70) | EGFRKDREPHB4ERBB2FBP1 | |
| SCHEMBL1446382 | 0.90 | EGFR (0.70) | EGFRKDREPHB4ERBB2FBP1 | |
| SCHEMBL29623600 | 0.90 | EGFR (0.70) | EGFRKDREPHB4ERBB2FBP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120046284-A1 | Salts and hydrates of 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(cis-4--cyclohexan-1-yloxy)-7-methoxy-quinazoline, their use as a medicament and the preparation thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046284-A1 | Salts and hydrates of 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(cis-4--cyclohexan-1-yloxy)-7-methoxy-quinazoline, their use as a medicament and the preparation thereof | CSNK1D, CSNK1A1, CSNK1A1L | EGFR 412/4885KDR 3643/4885EPHB4 3887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.